^
    17h
    Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma (clinicaltrials.gov)
    P2, N=90, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Mar 2027 --> Jul 2027 | Trial primary completion date: Mar 2027 --> Jul 2027
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    6d
    CA224-056: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer (clinicaltrials.gov)
    P2, N=80, Recruiting, Dan Zandberg | Trial completion date: Sep 2027 --> Sep 2026 | Trial primary completion date: May 2027 --> May 2026
    Trial completion date • Trial primary completion date • Combination therapy • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • LAG3 (Lymphocyte Activating 3)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    7d
    Study of ZGGS15 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting --> Active, not recruiting | N=36 --> 22 | Trial completion date: Aug 2024 --> Aug 2026 | Trial primary completion date: Aug 2024 --> Aug 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    ZGGS15
    9d
    Agilent Companion Diagnostic Assay PD-L1 IHC 28-8 pharmDx Receives European IVDR Certification (Businesswire)
    "Agilent’s PD-L1 IHC 28-8 pharmDx (Code SK005) provides clinically relevant information about PD-L1 expression – a critical biomarker for potential response to therapies containing anti-PD-1 antibodies such as OPDIVO (nivolumab) which has demonstrated therapeutic value across growing list of cancer types and Opdualag (nivolumab and relatimab)....PD-L1 IHC 28-8 pharmDx (Code SK005) has received European IVDR certification for nine cancer indications, including five companion diagnostic indications; non-small cell lung cancer (NSCLC), muscle invasive urothelial carcinoma (MIUC), melanoma, esophageal squamous cell carcinoma (ESCC), and gastric, gastroesophageal junction (GEJ) and esophageal adenocarcinoma."
    PD-L1 IHC 28-8 pharmDx
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw)
    9d
    A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Feb 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)
    11d
    Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial. (PubMed, ESMO Open)
    Results showed antitumour activity and manageable safety with NIVO + RELA. Findings also support NIVO + IPI as an effective combination regimen in IO-naive patients with aRCC.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3) • RELA (RELA Proto-Oncogene)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    13d
    CA209-1451: Neoadjuvant Opdualag Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, University of California, San Diego | Initiation date: Oct 2024 --> Jan 2025
    Trial initiation date
    |
    Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    13d
    A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • nivolumab subcutaneous (BMS-986298)
    14d
    CA224-094: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=27, Active, not recruiting, Jose Lutzky, MD | Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Jan 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    15d
    RELATIVITY-127: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (clinicaltrials.gov)
    P3, N=570, Recruiting, Bristol-Myers Squibb | Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Feb 2025 --> Aug 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw)
    24d
    TQB2223-AK105-Ib-01: Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. (clinicaltrials.gov)
    P1, N=34, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Anniko (penpulimab) • TQB2223
    28d
    A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial • Metastases
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    29d
    A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=413, Not yet recruiting, Bristol-Myers Squibb
    New P1/2 trial • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • Opdualag (nivolumab/relatlimab-rmbw) • nivolumab subcutaneous (BMS-986298)
    29d
    A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Mar 2028 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • tobemstomig (RG6139)
    1m
    AK137-101: AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=87, Not yet recruiting, Akeso
    New P1 trial • Metastases
    1m
    RELATIVITY-106: A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (clinicaltrials.gov)
    P1/2, N=162, Recruiting, Bristol-Myers Squibb | Trial primary completion date: Jun 2024 --> Oct 2025
    Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • relatlimab (BMS-986016)
    1m
    Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma (clinicaltrials.gov)
    P2, N=90, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Phase classification: P1 --> P2
    Phase classification
    |
    PD-L1 (Programmed death ligand 1)
    |
    Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    1m
    A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer (clinicaltrials.gov)
    P2, N=210, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    1m
    Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    1m
    An open-label, multicenter Phase 2 single-arm, study to assessing the efficacy and safety of DNV3 in combination with toripalimab and chemotherapy in patients with locally advanced unresectable or metastatic melanoma following failure of prior treatment with immune checkpoint inhibitors (ChiCTR2400091269)
    P2, N=60, Not yet recruiting, Fujian Cancer Hospital; Fujian Cancer Hospital
    New P2 trial • Combination therapy • Checkpoint inhibition • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Loqtorzi (toripalimab-tpzi)
    1m
    Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors (clinicaltrials.gov)
    P1, N=33, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    1m
    Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies. (PubMed, MAbs)
    We characterized the differences between serplulimab with approved PD-1/PD-L1 inhibitors (pembrolizumab and nivolumab) in terms of their binding features and functions in vitro and anti-tumor activity in vivo. Mechanistically, the serplulimab combination effectively reduces tumor microenvironment Treg cell populations, augments effector and memory T cell populations, and more potently modulates genes associated with diverse facets of the immune system, surpassing the effects of the pembrolizumab combination. In summary, our data underscore serplulimab as a differentiated PD-1 monoclonal antibody with best-in-class therapeutic potential.
    Preclinical • Journal • Combination therapy
    |
    LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Hetronifly (serplulimab)
    2ms
    KEYFORM-007: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study (clinicaltrials.gov)
    P3, N=94, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Nov 2025 --> Feb 2025
    Trial completion date • Metastases
    |
    Keytruda (pembrolizumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • favezelimab/pembrolizumab (MK-4280A)
    2ms
    KEYFORM-007: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) (clinicaltrials.gov)
    P3, N=505, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Nov 2025 --> Feb 2025
    Trial completion date • Metastases
    |
    Keytruda (pembrolizumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • favezelimab/pembrolizumab (MK-4280A)
    2ms
    R3767-ONC-2011: Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (clinicaltrials.gov)
    P3, N=1535, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Aug 2032 --> Jun 2031 | Trial primary completion date: Mar 2026 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    2ms
    Monoclonal Antibody against Porcine LAG3 Inhibits Porcine Reproductive and Respiratory Syndrome Virus Infection. (PubMed, Vet Sci)
    Interference of LAG3 expression on PHA-activated lymphocytes promoted PRRSV replication in the co-culture system of monocyte-derived dendritic cells and lymphocytes, whereas overexpression of LAG3 or blocking of the LAG3 signal with mAb 1C2 inhibited PRRSV replication, indicating that PRRSV infection activates the LAG3-signaling pathway, suggesting that this pathway plays an important role in PRRSV pathogenesis. The results obtained lay the foundation for subsequent research on the role of LAG3 in PRRS and other diseases with persistent infection characteristics.
    Preclinical • Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3)
    |
    LAG3 expression • LAG3 overexpression
    2ms
    LBL-007-CN-004: A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors (clinicaltrials.gov)
    P1/2, N=490, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    cisplatin • gemcitabine • docetaxel • Tevimbra (tislelizumab-jsgr) • LBL-007
    2ms
    Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor (clinicaltrials.gov)
    P2, N=42, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial completion date • Trial primary completion date • Mismatch repair • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    2ms
    Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements. (PubMed, Biomark Res)
    Currently, with the approval of relatlimab, a LAG-3 blocking antibody, a third player, has been used in the fight against cancer...However, the complex biology of LAG-3 may hinder its full development as a therapeutic alternative. In this review, we provide in-depth insight into the biology of LAG-3 and its current and future development in cancer treatment.
    Review • Journal
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    favezelimab (MK-4280) • fianlimab (REGN3767) • relatlimab (BMS-986016)
    2ms
    R3767-ONC-2208: A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma (clinicaltrials.gov)
    P2/3, N=520, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    2ms
    Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC (clinicaltrials.gov)
    P2, N=2, Terminated, Shanghai Henlius Biotech | N=49 --> 2 | Trial completion date: Apr 2026 --> Dec 2023 | Suspended --> Terminated | Trial primary completion date: Aug 2024 --> Dec 2023; Due to poor clinical trial accrual, the study was terminated.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • KRAS wild-type • RAS wild-type
    |
    Hetronifly (serplulimab) • HLX26
    2ms
    A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=280, Not yet recruiting, Akeso
    New P1/2 trial • Combination therapy
    |
    ligufalimab (AK117)
    2ms
    Phase II Trial of Immunotherapy in Patients with Carcinomas Arising from the Renal Medulla (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    SMARCB1 negative
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    3ms
    Neoadjuvant Opdualag Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, University of California, San Diego
    New P2 trial
    |
    Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    3ms
    Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=320, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 expression
    |
    tobemstomig (RG6139)
    3ms
    A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=210, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Oct 2026 | Trial primary completion date: Sep 2024 --> May 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Checkpoint inhibition • Metastases
    |
    Keytruda (pembrolizumab) • Inlyta (axitinib) • tiragolumab (RG6058) • tobemstomig (RG6139)
    3ms
    Design and Biophysical Characterization of Second-Generation cyclic peptide LAG-3 inhibitors for cancer immunotherapy. (PubMed, Bioorg Med Chem Lett)
    A per-residue decomposition of the interaction energy indicated that the 3-cyano group in cyclic peptide 12 contributes to a more favorable conformation, yielding an interaction energy of -9.22 kcal/mol with Phe443 of MHC-II, compared to -6.03 kcal/mol and -5.619 kcal/mol for cyclic peptides 0 and 5, respectively. Despite promising in vitro results, cyclic peptide 12 failed to inhibit tumor growth in vivo, underscoring the importance of dual immunotherapies targeting several immune checkpoints to achieve anti-tumor efficacy.
    Journal
    |
    LAG3 (Lymphocyte Activating 3)
    3ms
    Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting (clinicaltrials.gov)
    P2, N=42, Completed, John Kirkwood | Active, not recruiting --> Completed | Trial completion date: Jul 2027 --> Jul 2024 | Trial primary completion date: Jul 2027 --> Jul 2024
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3)
    |
    PD-1 expression • LAG3 expression
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    3ms
    RELATIVITY1093: A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (clinicaltrials.gov)
    P3, N=800, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • pemetrexed • Opdualag (nivolumab/relatlimab-rmbw)
    3ms
    BGB-900-102: Study of BGB-A425 and LBL-007 in Combination with Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=358, Recruiting, BeiGene | Trial completion date: Dec 2027 --> Apr 2025 | Trial primary completion date: Mar 2026 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • LBL-007 • surzebiclimab (BGB-A425)
    3ms
    A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov)
    P1, N=88, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Aug 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    Loqtorzi (toripalimab-tpzi) • Inlyta (axitinib) • LBL-007
    3ms
    Real-world treatment patterns and outcomes of patients with advanced melanoma treated with nivolumab plus relatlimab. (PubMed, Oncologist)
    Our retrospective review at a tertiary cancer center of patients with stage 3 and 4 melanoma treated with NIVO-RELA revealed an overall response rate (ORR) of 39%, with notable improvements in median PFS and ORR, especially in first-line treated patients. Our study highlights the superior efficacy of NIVO-RELA over previous reports, demonstrating its significant potential in the treatment landscape of advanced melanoma.
    Journal • HEOR • Real-world evidence • Real-world • Metastases
    |
    LAG3 (Lymphocyte Activating 3) • RELA (RELA Proto-Oncogene)
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)